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doi:10.1016/j.jtcvs.2004.03.056Objective: To define the most reliable prognostic factor, we studied the 5-year
survival of patients after resection of pulmonary metastases from colorectal cancer
in relation to various prognostic factors, including vascular endothelial growth
factor expression in primary and metastatic tumors.
Methods: A retrospective study was undertaken in 49 patients who had undergone
complete resection of pulmonary metastasis from colorectal carcinoma. All patients
were retrospectively analyzed for sex, age, location and stage of primary tumor,
number of pulmonary metastases, type of pulmonary resection, size of metastatic
tumor, lymph node metastasis, and prethoracotomy carcinoembryonic antigen level.
Furthermore, vascular endothelial growth factor expression of both primary and
metastatic tumors was investigated.
Results: Overall 5-year survival was 34.3%. In the univariate analysis the number of
pulmonary metastases (P .007) and vascular endothelial growth factor expression
in metastatic tumors (P  .008) and primary colorectal tumors (P  .011) were
significantly associated with poor survival. In the multivariate analysis the number
of pulmonary metastases (P .0031), vascular endothelial growth factor expression
in metastatic tumors (P  .0057), and stage of primary tumor (P  .0321) were
characteristics that retained a significant independent prognostic effect on overall
survival. A statistically significant difference was not found in the 5-year survival of
patients with solitary and negative vascular endothelial growth factor expression in
metastatic tumors (59.1%) versus those with multiple and positive vascular endo-
thelial growth factor expression in metastatic tumors (10.0%; P  .0001).
Conclusions: Vascular endothelial growth factor expression in metastatic pulmonary
tumors is an important prognostic marker for patients with pulmonary metastasis
from colorectal carcinoma. Our results suggested that patients with multiple and
positive vascular endothelial growth factor expression in the metastatic tumor will
not receive benefit from metastasectomy.
Pulmonary metastasis is the most common extra-abdominal manifes-tation of advanced colorectal cancer. Blalock1 first reported a surgicalresection for pulmonary metastasis from colorectal carcinoma in1944. To date, there is no effective chemotherapeutic treatment avail-able for metastatic colorectal cancer. Thus far, surgical interventionremains the only effective treatment for patients with limited meta-
static disease. Several prognostic factors affecting survival after a resection of
pulmonary metastasis from colorectal carcinoma have been suggested. However,
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prognostic factors, and controversy remains over which
factors are the best indicators for surgical resection. To
better define the reliability of prognostic factors, we studied
the 5-year survival of patients after resection of pulmonary
metastasis from colorectal cancer in relation to various
prognostic factors, including vascular endothelial growth
factor (VEGF) expression in primary and metastatic tumors.
Patients and Methods
Forty-nine patients (35 male and 14 female patients) underwent
pulmonary resection of metastasis lesions from colorectal cancer
between April 1984 and March 2001 in our institute. There were
no hospital deaths within 30 days after thoracotomy. In all patients,
metastasectomy was performed after confirming that the metastatic
site was confined to the lung. The extrathoracic metastasis was
ruled out preoperatively by means of brain magnetic resonance
imaging, radionuclide bone scanning, and abdominal computed
tomography. A barium enema or colonofiberoscopy was used to
confirm that the primary site was not recurrent. Complete resection
of the pulmonary metastasis was performed in all cases. Although
wedge resection for the pulmonary metastatic tumor was per-
formed in principle, lobectomy or pneumonectomy was per-
formed, taking the size and position of the tumors into account.
Histologic proof of diagnosis was available from all resected lung
TABLE 1. The characteristics of 49 patients undergoing
resection of pulmonary metastasis from colorectal cancer
No. of patients
Sex
Male 35
Female 14
Age (y)
Average 62.9
Range 43–79
Location of primary cancer
Colon 26
Rectum 23
Stage of primary cancer
Dukes A 9
Dukes B 14
Dukes C 26
No. of pulmonary metastases
Solitary 26
Multiple 23
No. of resections
1 40
2 9
Site of pulmonary metastasis
Unilateral 7
Bilateral 42
Type of pulmonary resection
Wedge resection 28
Segmentectomy 8
Lobectomy 12
Pneumonectomy 1lesions. Lymph node biopsy was performed when the metastasis
518 The Journal of Thoracic and Cardiovascular Surgery ● Octowas suspected preoperatively or intraoperatively. Nineteen patients
had received their colorectal operations at other hospitals. Staging
of the primary colon lesion was confirmed through a review of the
surgical and pathologic records. Patient records were reviewed for
sex, age, location and stage of primary tumor, number of pulmo-
nary metastases, type of pulmonary resection, size of metastatic
tumor, lymph node metastasis, and prethoracotomy carcinoembry-
onic antigen (CEA) level. Furthermore, VEGF expression of both
primary and metastatic tumors was investigated.
Table 1 summarizes the characteristics of the 49 patients.
Patient age ranged from 43 to 79 years, with an average of 62.9
years. The primary lesion was located on the colon in 26 patients
and on the rectum in 23 patients. The distribution of Dukes’ stage
of primary colorectal cancer is given in Table 1. Twenty-six
patients had a solitary metastasis, and 23 had multiple metastases.
Nine patients underwent pulmonary metastasis resection more than
twice. Seven patients underwent bilateral pulmonary resection. A
wedge resection was performed in 28 patients, segmentectomy in
8 patients, lobectomy in 12 patients, and pneumonectomy in 1
patient. In 15 patients the nodal status could not be determined.
Sampling of lymph nodes was performed in 34 patients. Thirteen
patients had hilar or mediastinal lymph node metastasis.
The expression of VEGF in cancer cells at the primary site and
metastatic tumors was also immunohistochemically assessed by
using the labeled streptavidin-biotin method, as described previ-
ously.2,3 For the primary antibody, we used the anti-VEGF poly-
clonal antibody (Santa Cruz Biotechnology Inc, Heidelberg, Ger-
many) diluted 100-fold. Paraffin-embedded sections of the
invasive edges of the tumors were reacted with the antibody for 2
hours at room temperature. The second antibody used was biotin-
labeled goat anti-mouse immunoglobulin (DAKO). The immuno-
reactivities for VEGF were graded as (), (), and () accord-
ing to the staining intensity of the tumor cells: () represents 0%
or less than 10% positive staining area, () represents 10% to 50%
positive staining area, and () represents more than 50% posi-
tive staining area. In this study we defined a tumor with the
strongest stain () as positive VEGF expression.2 Positivity was
evaluated by 2 independent observers without knowledge of the
clinicopathologic factors. The mean follow-up period was 102 
45 months.
The survival was calculated from the date of the pulmonary
resection according to the Kaplan-Meier method. The influence of
variables on survival was analyzed by using the log-rank test for
discrete variables and the Cox proportional hazards model for
continuous variables.
Results
The overall cumulative 5-year survival was 34.3%. The
5-year survival was 46.3% for patients with a solitary me-
tastasis (n  26) compared with 18.2% for those with 2 or
more metastases (n  23; P  .006; Figure 1). The 5-year
survival for the 19 patients with a prethoracotomy CEA
level of less than 2 ng/mL was 48.3% compared with 25.7%
for the 30 patients with a CEA level of 2 ng/mL or greater
(P  .061). The 5-year survival for patients with a lymph
node metastasis was 38.5% compared with 23.1% for those
without a lymph node metastasis. There was no statistically
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TSsignificant difference between the 2 groups (P  .216). The
association of other prognostic variables, such as the num-
ber of resections and the site of pulmonary metastasis,
revealed no significant difference in survival (P  .346 and
P .248, respectively). The VEGF expression in metastatic
tumor significantly influenced survival (P  .0046). The
5-year survival was 46.1% for patients with negative VEGF
expression in the metastatic tumor versus 18.0% for patients
with positive VEGF expression (Figure 2).
The univariate analysis revealed that stage of primary
tumor (P  .028), number of pulmonary metastases (P 
.007), prethoracotomy CEA level (P  .059), VEGF ex-
pression in metastatic tumor (P  .008), and VEGF expres-
sion in primary tumor (P  .011) were significantly asso-
Figure 2. Survival curves by VEGF expression in metastatic tu-
mors. The prognosis for patients with positive VEGF expression in
a metastatic tumor was significantly low (P  .0046).
Figure 1. Patient survival by number of metastatic lesions. The
cumulative survival for 26 patients with a solitary pulmonary
metastasis was 46.3% at 5 years, whereas that for 23 patients
with 2 or more pulmonary metastases was 18.2% (P  .006).ciated with poor survival (Table 2). The multivariate
The Journal of Thoracianalysis revealed that number of pulmonary metastases (P
 .0031), VEGF expression in metastatic tumor (P 
.0057), and stage of primary tumor (P  .0321) were
characteristics that retained a significant independent prog-
nostic effect on overall survival (Table 3). A statistically
TABLE 2. Prognostic effect of clinicopathologic and bio-
logic factors on survival (univariate analysis)
Factors P value Hazard ratio 95% CI
Age, y (66 vs 66) .9 1.05 0.50–2.10
Sex (male vs female) .88 1.06 0.47–2.23
Primary site (colon vs
rectum)
.96 0.98 0.49–2.01
Stage of primary cancer
(Dukes A, B vs Dukes C)
.028 1.98 0.95–4.15
No. of pulmonary
metastases (solitary vs
multiple)
.0067 2.82 1.38–5.70
Type of pulmonary resection
(partial vs other)
.5 1.15 0.75–1.70
CEA level, ng/mL (2.0 vs
2.0)
.059 1.92 0.97–4.26
Metastatic tumor size, mm
(30 vs 30)
.83 0.93 0.45–1.86
Disease-free interval, y (2
vs 2)
.79 0.92 0.52–1.71
VEGF (metastatic site)
(positive vs negative)
.0078 2.71 1.32–5.64
VEGF (primary site) (positive
vs negative)
.011 2.17 1.14–12.3
CI, Confidence interval; CEA, carcinoembryonic antigen; VEGF, vascular
endothelial growth factor.
Figure 3. Survival curves in relation to the number of metastases
and VEGF expression in metastatic tumors. The cumulative sur-
vival for 16 patients with a solitary metastasis with negative VEGF
expression was 59.1% at 5 years, whereas that for 10 patients
with multiple metastases with positive VEGF expression was
10.0% (P < .0001).significant difference (P  .0001) was found in the 5-year
c and Cardiovascular Surgery ● Volume 128, Number 4 519
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pression in the metastatic tumor (n  16) versus those with
multiple and positive VEGF expressions in the metastatic
tumor (n  10; 59.1% and 10.0%, respectively; Figure 3).
Discussion
Pulmonary metastases from colorectal carcinoma in most
patients are multiple and a subsequent expression of gener-
alized metastatic disease.4,5 There still exists a subgroup of
patients in whom the only site of recurrence is the lung.4 In
this study patients with pulmonary metastases from colo-
rectal carcinoma underwent surgical intervention after con-
firming that no other recurrence had existed, including at the
primary site. Several studies concerning operations for pul-
monary metastasis from colorectal carcinoma have been
published, and the 5-year survivals reported ranged from
9% to 42%.6-12 In this study all patients underwent complete
resection of all pulmonary metastases, and the overall
5-year survival was 34.3%.
A number of prognostic factors affecting survival after a
resection of pulmonary metastasis from colorectal carcino-
mas have been reported in other series (Table 4). 6-13 How-
ever, the survival in relation to the prognostic factors varied
among the institutions, and it remains unclear as to which
factors are the best indicators for surgical resection. The
number of metastases was a significant prognostic factor in
most studies.6-11,13 On the other hand, Inoue and col-
leagues12 reported that there was no significant difference in
survival between patients with solitary and multiple lesions
and asserted that most of these analyses included cases
involving incompletely resected multiple metastases. It is
possible that the more pulmonary metastasis that exists at
the time of resection, the more likely that micrometastases
are latent in the lung. In our study we observed a significant
association between the number of pulmonary metastases
and postthoracotomy survival. The multivariate analysis
revealed that the number of metastases was a characteristic
that retained a significant independent prognostic effect on
overall survival (P  .0031). In the presented study more
than 4 tumors were resected in 13 patients.
Recently, several reports have revealed that the progno-
sis of patients with increased prethoracotomy serum CEA
10,12,13
TABLE 3. Multivariate analysis by means of Cox proportio
Factors
Characterist
Unfavorable
No. of pulmonary metastases Multiple
VEGF (metastatic site) Positive
Stage of primary cancer Dukes C
CEA level 2.0 ng/mL
CI, Confidence interval; VEGF, vascular endothelial growth factor; CEA, calevels was poor. In our study the patients with normal
520 The Journal of Thoracic and Cardiovascular Surgery ● Octoprethoracotomy serum CEA levels who underwent pulmo-
nary metastasectomies had a significantly higher 5-year
survival than those with high serum CEA levels (48.3% vs
25.7%), but CEA was not an independent prognostic factor
according to the multivariate analysis. In this study the
presence of lymph node metastasis did not seem to affect
the patients’ prognoses. This result might have been influ-
enced by the fact that lymph node dissection or sampling
was not performed in some of the patients (15 of 49). Inoue
and colleagues12 reported that hilar or mediastinal lymph
node metastasis influences the postthoracotomy survival.
They had examined the presence of lymph node metastasis
in all of the patients to clarify the incidence of lymph node
involvement. Pfannschmidt and associates13 reported that
thoracic lymph node metastasis was identified as a prognos-
tic-related criteria for surgical intervention, and pulmonary
resection of a single nodule without systematic lymph node
dissection is not recommended.
Tumor angiogenesis is a fundamental step in the growth
and progression of solid tumors and also an important step
of the complex metastatic system.14 VEGF is associated
with tumor progression through various biologic functions,
such as immune reactions mediated by the maturation of
dendritic cells, migration of tumor cells, malignant trans-
formation and invasion, tumor survivability, and tumor an-
giogenesis.15-20 To our knowledge, no studies have ad-
dressed the clinical significance of VEGF expression of
metastatic lung tumor. In this study we investigated the
expression of VEGF in both primary colorectal tumors and
metastatic lung tumors. Furthermore, we investigated
whether VEGF expression in the tumor is a prognostic
factor. In most cases VEGF expression was positive in
primary colorectal tumors, whereas its expression was neg-
ative in the metastatic tumors. Twenty of 38 cases revealed
negative VEGF expression in the metastatic pulmonary
tumor, although results were positive in primary colorectal
tumors. The characteristics of metastatic lung tumors are
sometimes different from those of primary colorectal can-
cer. The decreased expression of VEGF might indicate that
the tumor growth is in a dormant state. The multivariate
analysis revealed that the number of pulmonary metastases
and VEGF expression in metastatic tumors were character-
hazard regression model
P value Hazard ratio (95% CI)avorable
Solitary .0031 3.20 (1.48–7.20)
egative .0057 3.20 (1.41–7.29)
ukes A,B .0321 1.69 (1.09–2.91)
2.0 ng/mL .1015 1.46 (0.61–3.69)
embryonic antigen.nal
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served in patients with single and negative VEGF expressions
in the metastatic tumor (59.1%). On the contrary, patients with
multiple metastases with positive VEGF expression showed
poor 5-year survivals (10.0%). Such results indicates that it
might be possible to select efficiently the patients who are
candidates for metastasectomy by taking into consideration
both the number of metastases and the level of VEGF expres-
sion in the metastatic tumor. For the treatment of patients with
multiple pulmonary metastases from colorectal cancer, open
excisional biopsy should be performed for one of the tumors,
and VEGF expression should be examined. Two-staged oper-
ation is desirable for the cases that reveal negative VEGF
expression in the metastatic tumor. If the tumor reveals posi-
tive VEGF expression, further treatment should be carefully
planned to avoid unnecessary operations. By using video-
assisted thoracic surgery, not only can tumor biopsy be per-
formed less invasively, but also cases that will not receive
benefit from surgical treatment can be ruled out. Needle biopsy
of excisional biopsy of the tumor should be performed for
patients with multiple metastases from colorectal cancer, and
the VEGF expression should be examined.
It is desirable to evaluate the VEGF expression in the
metastatic tumor preoperatively. In this study VEGF ex-
pression was evaluated by using paraffin-embedded tumor
sections. We reported that there was a significant correlation
between circulating VEGF levels and intratumoral VEGF
levels in patients with primary non–small cell lung cancer.21
Werther and coworkers22 analyzed the prognostic value of
matched preoperative serum and plasma VEGF concentra-
tions in patients with colorectal cancer. This study indicated
that preoperative serum VEGF expression is a better pre-
dictor of overall survival than plasma VEGF expression, but
in comparison with other prognostic factors, the reliability
TABLE 4. Review of the prognostic factors for resectable
Author and reference no.
Published
year n
5-y
survival
(%)
No. of
metastases
S
me
Wilking and coworkers6 1985 27 9 
Mansel and coworkers7 1986 66 38 
Brister and coworkers8 1988 27 21 *
Goya and coworkers9 1989 65 42 
McAfee and
coworkers10
1992 139 30.5 
Yano and coworkers11 1993 27 41.1 
Inoue and coworkers12 2000 25 39.2 
Pfannschmidt and
coworkers13
2003 167 32.4 
Our report 2003 49 34.3 
DFI, Disease-free interval; CEA, carcinoembryonic antigen; LN, lymph nodeof serum VEGF expression is not yet proved. Further pro-
The Journal of Thoracispective study is required to investigate whether circulating
VEGF levels reflect the VEGF expression in the metastatic
tumor and can be regarded as a prognostic marker for
patients with pulmonary metastases from colorectal cancer.
In conclusion, the number of pulmonary metastatic tu-
mors and positive VEGF expression in metastatic tumor are
the most reliable factors that determine long-term survival
of the patients with resectable pulmonary metastasis from
colorectal carcinoma. Our results suggested that patients
with multiple and positive VEGF expression in the meta-
static tumor will not receive benefits from metastasectomy.
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